PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.

Alessandra RomanoNunziatina Laura ParrinelloPiera La CavaDaniele TibulloCesarina GiallongoGiuseppina CamioloFabrizio PuglisiMarina ParisiMaria Cristina PirosaEnrica MartinoConcetta ConticelloGiuseppe Alberto PalumboFrancesco Di Raimondo

Published in: Expert review of molecular diagnostics (2018)

In MM, Arg-1 is mainly expressed by PMN-MDSC. PMN-MDSC and Arg-1 are reduced in vivo after lenalidomide but not bortezomib treatment.

Keyphrases

multiple myeloma
newly diagnosed
combination therapy
nitric oxide
mesenchymal stem cells
nitric oxide synthase
high dose